tradingkey.logo
๎™ผ
tradingkey.logo
๎™๊ฒ€์ƒ‰
๎™

Neuphoria Therapeutics Inc

NEUP
๎˜ญ๊ด€์‹ฌ ๋ชฉ๋ก์— ์ถ”๊ฐ€
2.550USD
-0.030-1.16%
์ข…๊ฐ€ย 11-13 16:00๏ผˆET๏ผ‰
13.80M์‹œ๊ฐ€์ด์•ก
์†์‹คP/E TTM

Neuphoria Therapeutics Inc ์ •๋ณด ํšŒ์‚ฌ

Neuphoria Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need. Its lead drug candidate, BNC210, is an oral, proprietary, selective negative allosteric modulator of the ฮฑ7 nicotinic acetylcholine receptor, for the acute, as-needed treatment of social anxiety disorder and for the chronic treatment of post-traumatic stress disorder. BNC210 is a well-tolerated, broad-spectrum antianxiety experimental therapeutic, designed to restore neurotransmitter balance in relevant brain areas, providing rapid relief from stress and anxiety symptoms without the common pitfalls of sedation, cognitive impairment, or addiction. In addition, the Company has two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimerโ€™s disease and other central nervous system conditions.

Neuphoria Therapeutics Inc ํ”„๋กœํ•„

๎™Œ
์ข…๋ชฉ ์ฝ”๋“œ NEUP
ํšŒ์‚ฌ ์ด๋ฆ„Neuphoria Therapeutics Inc
์ƒ์žฅ์ผDec 21, 1999
CEOPapapetropoulos (Spyridon)
์ง์› ์ˆ˜7
์œ ํ˜•Ordinary Share
ํšŒ๊ณ„ ์—ฐ๋„ ์ข…๋ฃŒDec 21
์ฃผ์†Œ100 Summit Dr
๋„์‹œBURLINGTON
์ฆ๊ถŒ ๊ฑฐ๋ž˜์†ŒNASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐ€United States of America
์šฐํŽธ ๋ฒˆํ˜ธ01803
์ „ํ™”
์›น์‚ฌ์ดํŠธhttps://www.neuphoriatx.com/
์ข…๋ชฉ ์ฝ”๋“œ NEUP
์ƒ์žฅ์ผDec 21, 1999
CEOPapapetropoulos (Spyridon)

Neuphoria Therapeutics Inc์˜ ํšŒ์‚ฌ ์ž„์›์ง„

๎™Œ
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Dr. Jane Ryan, Ph.D.
Dr. Jane Ryan, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
7.01K
+96.72%
Mr. Peter Miles Winston (Miles Davies) Davies
Mr. Peter Miles Winston (Miles Davies) Davies
Non-Executive Independent Director
Non-Executive Independent Director
6.91K
+98.18%
Mr. David Ian Wilson
Mr. David Ian Wilson
Non-Executive Director
Non-Executive Director
6.90K
+98.30%
Mr. Alan Fisher
Mr. Alan Fisher
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Ms. Liz Doolin
Ms. Liz Doolin
Senior Vice President - Clinical Development
Senior Vice President - Clinical Development
--
--
Dr. Spyridon (Spyros) Papapetropoulos, M.D.
Dr. Spyridon (Spyros) Papapetropoulos, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Timothy M. (Tim) Cunningham, CPA
Mr. Timothy M. (Tim) Cunningham, CPA
Chief Financial Officer
Chief Financial Officer
--
--
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Dr. Jane Ryan, Ph.D.
Dr. Jane Ryan, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
7.01K
+96.72%
Mr. Peter Miles Winston (Miles Davies) Davies
Mr. Peter Miles Winston (Miles Davies) Davies
Non-Executive Independent Director
Non-Executive Independent Director
6.91K
+98.18%
Mr. David Ian Wilson
Mr. David Ian Wilson
Non-Executive Director
Non-Executive Director
6.90K
+98.30%
Mr. Alan Fisher
Mr. Alan Fisher
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Ms. Liz Doolin
Ms. Liz Doolin
Senior Vice President - Clinical Development
Senior Vice President - Clinical Development
--
--
Dr. Spyridon (Spyros) Papapetropoulos, M.D.
Dr. Spyridon (Spyros) Papapetropoulos, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--

์ž์ฃผ ๋ฌป๋Š” ์งˆ๋ฌธ

Neuphoria Therapeutics Inc์˜ ์ƒ์œ„ 5๋Œ€ ์ฃผ์ฃผ๋Š” ๋ˆ„๊ตฌ์ธ๊ฐ€์š”?

๎™Œ
Neuphoria Therapeutics Inc์˜ ์ƒ์œ„ 5๋Œ€ ์ฃผ์ฃผ๋Š” ๋‹ค์Œ๊ณผ ๊ฐ™์Šต๋‹ˆ๋‹ค: Dr. Jane Ryan, Ph.D.

Neuphoria Therapeutics Inc(NEUP)์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•œ ๊ธฐ๊ด€์€ ๋ช‡ ๊ฐœ์ž…๋‹ˆ๊นŒ?

๎™Œ
2026Q1 ๊ธฐ์ค€์œผ๋กœ, Neuphoria Therapeutics Inc์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•œ ๊ธฐ๊ด€์€ ์ด 38๊ณณ์ด๋ฉฐ, ์ด๋“ค์ด ๋ณด์œ ํ•œ ์ฃผ์‹์˜ ์ด ๊ฐ€์น˜๋Š” ์•ฝ 1.60M๋กœ ์ „์ฒด ๋ฐœํ–‰ ์ฃผ์‹์˜ 29.64%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค. ์ด๋Š” 2025Q4 ๋Œ€๋น„ -1798693.00 ์ฆ๊ฐ€ํ•œ ์ˆ˜์น˜์ž…๋‹ˆ๋‹ค.
tradingkey.logo
์œ„ํ—˜ ๊ฒฝ๊ณ : ์ €ํฌ ์›น์‚ฌ์ดํŠธ์™€ ๋ชจ๋ฐ”์ผ ์•ฑ์€ ํŠน์ • ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ผ๋ฐ˜์ ์ธ ์ •๋ณด๋งŒ์„ ์ œ๊ณตํ•ฉ๋‹ˆ๋‹ค. Finsights๋Š” ์žฌ์ •์  ์กฐ์–ธ์ด๋‚˜ ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜์ง€ ์•Š์œผ๋ฉฐ, ์ด๋Ÿฌํ•œ ์ •๋ณด ์ œ๊ณต์ด Finsights๊ฐ€ ๊ธˆ์œต ์กฐ์–ธ์ด๋‚˜ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜๋Š” ๊ฒƒ์œผ๋กœ ํ•ด์„๋˜์–ด์„œ๋Š” ์•ˆ ๋ฉ๋‹ˆ๋‹ค.
ํˆฌ์ž ์ƒํ’ˆ์€ ํˆฌ์ž ์›๊ธˆ ์†์‹ค์„ ํฌํ•จํ•œ ์ƒ๋‹นํ•œ ํˆฌ์ž ์œ„ํ—˜์— ๋…ธ์ถœ๋˜์–ด ์žˆ์œผ๋ฉฐ, ๋ชจ๋“  ์‚ฌ๋žŒ์—๊ฒŒ ์ ํ•ฉํ•˜์ง€ ์•Š์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค. ํˆฌ์ž ์ƒํ’ˆ์˜ ๊ณผ๊ฑฐ ์„ฑ๊ณผ๋Š” ๋ฏธ๋ž˜ ์„ฑ๊ณผ๋ฅผ ๋ณด์žฅํ•˜์ง€ ์•Š์Šต๋‹ˆ๋‹ค.
Finsights๋Š” ์ œ3์ž ๊ด‘๊ณ ์ฃผ๋‚˜ ์ œํœด์‚ฌ๊ฐ€ ์ €ํฌ ์›น์‚ฌ์ดํŠธ๋‚˜ ๋ชจ๋ฐ”์ผ ์•ฑ ๋˜๋Š” ๊ทธ ์ผ๋ถ€์— ๊ด‘๊ณ ๋ฅผ ๊ฒŒ์žฌํ•˜๊ฑฐ๋‚˜ ์ „๋‹ฌํ•  ์ˆ˜ ์žˆ๋„๋ก ํ—ˆ์šฉํ•  ์ˆ˜ ์žˆ์œผ๋ฉฐ, ์‚ฌ์šฉ์ž๊ฐ€ ๊ด‘๊ณ ์™€ ์ƒํ˜ธ์ž‘์šฉํ•˜๋Š” ๋ฐฉ์‹์— ๋”ฐ๋ผ ์ด๋“ค๋กœ๋ถ€ํ„ฐ ๋ณด์ƒ์„ ๋ฐ›์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.
ยฉ ์ €์ž‘๊ถŒ: FINSIGHTS MEDIA PTE. LTD. ๋ชจ๋“  ๊ถŒ๋ฆฌ ๋ณด์œ